Krebs Biochemicals & Industries Ltd. (KREBSBIO) AI Stock Analysis

• Market Cap: ₹1.42B
• Dividend Yield: N/A
• Average Volume (3M): 726.00
• Price to Earnings (P/E): ―
• Beta (1Y): 1.57
• Revenue Growth: -46.31%
• EPS Growth: -26.28%
• Country: IN
• Employees: 191
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -2.85
• Shares Outstanding: 21,560,587
• 10 Day Avg. Volume: 346
• 30 Day Avg. Volume: 726
• PEG Ratio: -0.15
• Price to Book (P/B): -1.00
• Price to Sales (P/S): 3.37
• P/FCF Ratio: -12.74
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: ₹68.00 ▼(-4.23% Downside)

Krebs Biochemicals & Industries Ltd. receives a low overall stock score due to significant financial distress, weak technical indicators, and poor valuation metrics. The company's ongoing financial challenges and lack of profitability are the most significant factors impacting the score.

Positive Factors

Business Model Strength

Krebs Biochemicals' business model of contract manufacturing and custom synthesis allows it to cater to specific client needs, enhancing market reach and providing a stable revenue stream.

Technological Advancements

By leveraging advanced fermentation and synthesis technologies, Krebs Biochemicals can maintain a competitive edge in the pharmaceutical industry, ensuring product quality and efficiency.

Market Position

Serving both domestic and international markets allows Krebs Biochemicals to diversify its revenue streams and reduce dependency on any single market, enhancing its resilience to regional economic fluctuations.

Negative Factors

Financial Distress

Ongoing financial distress, characterized by consistent losses and high leverage, poses a risk to long-term sustainability and limits the company's ability to invest in growth opportunities.

Balance Sheet Health

A highly leveraged balance sheet with negative equity indicates financial instability, increasing the risk of insolvency and limiting the company's financial flexibility.

Cash Flow Challenges

Persistent negative cash flow indicates inefficiencies in operations and challenges in sustaining business activities, potentially impacting the company's ability to meet financial obligations.

Krebs Biochemicals & Industries Ltd. Business Overview & Revenue Model

Company Description

Krebs Biochemicals & Industries Limited manufactures and sells active pharmaceutical ingredients in India. The company develops biotech processes for application in medicine, agriculture, and industry fields. Its products, such as androstenedione, lovastatin, and simvastatin for anti-cholesterol and steroid intermediate applications. The company is also developing various products, including amlodipine, cetirizine, orlistat, serratiopepetidase, telmisartan, and phenylephrine for anti-hypertension, anti-histamine, anti-obesity, anti-inflammatory, and cold and cough applications. In addition, it offers contract manufacturing services for large pharmaceutical and multinational companies. Krebs Biochemicals & Industries Limited was incorporated in 1991 and is headquartered in Hyderabad, India.

How the Company Makes Money

KREBSBIO generates revenue through multiple key streams: primarily, the sale of its proprietary biochemicals and enzymes to various industries, which accounts for a significant portion of its earnings. Additionally, the company engages in contract manufacturing and custom formulation services, allowing it to collaborate with other businesses to develop tailored solutions. Strategic partnerships with research institutions and industry leaders also enhance its product offerings and market reach, contributing to revenue growth. Furthermore, KREBSBIO invests in research and development to innovate and expand its product line, ensuring a competitive edge and continuous demand in the market.

Krebs Biochemicals & Industries Ltd. Financial Statement Overview

Summary

Krebs Biochemicals & Industries Ltd. faces significant financial challenges, including consistent losses, high leverage, and poor cash flow management. The negative net income, EBIT margins, and declining revenue highlight operational inefficiencies and financial distress.

Income Statement

Krebs Biochemicals & Industries Ltd. has consistently faced challenges in generating profits, with negative net income and EBIT margins over multiple years. The net profit margin and EBIT margin are significantly negative, indicating ongoing operational difficulties. Revenue has been declining, and the gross profit margin is also poor, highlighting inefficiencies in cost management and sales performance.

Balance Sheet

The balance sheet reveals a highly leveraged position with a negative stockholders' equity, indicating financial instability. The debt-to-equity ratio is unfavorable due to the high level of debt relative to equity, and the equity ratio is negative, underscoring the company's risk of insolvency. This presents a significant risk for creditors and investors.

Cash Flow

Krebs Biochemicals & Industries Ltd. has struggled with cash flow management, as evidenced by negative free cash flow and operating cash flow across multiple years. The free cash flow to net income ratio is poor, indicating that the company is not effectively converting its earnings into cash. This ongoing cash flow issue poses a challenge for sustaining operations and meeting financial obligations.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	359.04M	433.12M	504.21M	521.34M	597.03M	386.06M
Gross Profit	313.17M	377.56M	-108.75M	244.19M	-57.64M	-136.26M
EBITDA	-142.34M	-143.21M	-82.73M	-151.62M	-328.46M	-169.63M
Net Income	-270.92M	-269.39M	-197.28M	-246.92M	-445.27M	-283.59M
Balance Sheet
Total Assets	0.00	1.69B	1.78B	1.75B	1.90B	1.59B
Cash, Cash Equivalents and Short-Term Investments	1.42M	3.38M	1.37M	858.00K	1.01M	7.11M
Total Debt	0.00	2.12B	2.39B	1.83B	1.88B	1.11B
Total Liabilities	1.46B	3.15B	2.97B	2.74B	2.65B	2.02B
Stockholders Equity	-1.46B	-1.46B	-1.19B	-994.62M	-750.93M	-427.33M
Cash Flow
Free Cash Flow	0.00	-114.54M	-70.50M	-355.84M	-407.36M	-400.81M
Operating Cash Flow	0.00	-78.91M	23.65M	-247.13M	-172.16M	-145.75M
Investing Cash Flow	0.00	-49.70M	-78.17M	-126.45M	-229.00M	-225.49M
Financing Cash Flow	0.00	128.65M	55.64M	373.43M	395.06M	376.61M

Krebs Biochemicals & Industries Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 71.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:KREBSBIO, the sentiment is Negative. The current price of 71 is above the 20-day moving average (MA) of 69.07, above the 50-day MA of 68.48, and below the 200-day MA of 75.19, indicating a bearish trend. The MACD of -0.31 indicates Positive momentum. The RSI at 40.75 is Neutral, neither overbought nor oversold. The STOCH value of 3.27 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:KREBSBIO.

Krebs Biochemicals & Industries Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ALPA	70 Neutral	₹1.59B	8.53	―	―	14.53%	-10.49%
BAFNAPH	65 Neutral	₹3.31B	37.74	―	―	-0.77%	2055.99%
BALPHARMA	58 Neutral	₹1.16B	14.25	―	1.62%	-9.07%	5.36%
VAISHALI	54 Neutral	₹918.64M	-291.50	―	―	18.35%	-154.65%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AAREYDRUGS	46 Neutral	₹1.97B	55.15	―	―	-17.47%	-50.07%
KREBSBIO	41 Neutral	₹1.42B	-5.17	―	―	-46.31%	-26.28%

Krebs Biochemicals & Industries Ltd. Corporate Events

Krebs Biochemicals to Shut Trading Window Ahead of Q3 Results

Krebs Biochemicals & Industries Ltd. has announced that, in line with SEBI (Prohibition of Insider Trading) Regulations, 2015, it will close its trading window for dealings in its securities from the close of business on 31 December 2025 until 48 hours after the declaration of its unaudited financial results for the third quarter and nine months ended 31 December 2025. The restriction applies to promoters, directors, designated persons, their immediate relatives and other connected parties, and signals the company’s preparation for its upcoming financial disclosure, with the exact date of the board meeting to consider these results to be communicated to the exchanges in due course.